EverSource Wealth Advisors’s Monopar Therapeutics MNPR Stock Holding History

EverSource Wealth Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$80	Buy	+1	New	+$107	﹤0.01%	4422

Other funds holding MNPR

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Gerber LLC Columbus, Ohio $220M AUM 16.73% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

EverSource Wealth Advisors's MNPR Position: Q3 2026 in Review

EverSource Wealth Advisors opened a new position in Monopar Therapeutics (MNPR) in Q3 2026: 1 share worth $80. The stake represents ﹤0.01% of the portfolio and ranks #4422 among its holdings.

23 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

EverSource Wealth Advisors held 1 share of Monopar Therapeutics worth $80 as of Q3 2026.
Monopar Therapeutics was a new EverSource Wealth Advisors position in Q3 2026.
Monopar Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q3 2026, its #4422 holding.
23 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on EverSource Wealth Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.